Utility of Remote Lung Auscultation in Transitions of Care After Pulmonary Exacerbations of COPD
Launched by STRADOS LABS, INC. · Dec 14, 2022
Trial Information
Current as of January 14, 2025
Withdrawn
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Males and females between the ages of 35 and 75 with documented physician-diagnosed COPD
- • 2. Hospitalization with a primary diagnosis of COPD with exacerbation or pneumonia.
- • 3. Patient able and willing to provide informed consent.
- • 4. Patient can follow study procedures, including instructions for self-placement and operation of device
- • a. Patient has experience using a smartphone
- • 5. Accessible by telehealth/telephone upon discharge
- • 6. Patient is able and willing to return to study site for study follow-up visits as necessary
- Exclusion Criteria:
- • 1. Patient unable or unwilling to provide informed consent
- • 2. Diagnosis of COPD is uncertain
- • 3. Plan for discharge to location other than the patient's home (eg, Nursing Home, Rehabilitation facility)
- • 4. Patient with end-stage medical condition with expected survival no more than 3 months
- • 5. History of adverse reaction or allergy to TegaDerm®
- • 6. Inaccessible by telehealth/telephone post discharge
About Strados Labs, Inc.
Strados Labs, Inc. is an innovative clinical trial sponsor focused on advancing respiratory health through the integration of cutting-edge technology and data analytics. Specializing in the development of non-invasive monitoring solutions, Strados Labs aims to enhance patient outcomes in respiratory diseases by providing real-time insights and comprehensive data to clinical researchers and healthcare professionals. Committed to improving the quality of care, the company leverages its proprietary platforms to facilitate more efficient and effective clinical trials, ultimately driving the discovery of novel therapies and interventions in respiratory medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials